Skip to main content

Cardiovascular Syst(CSII-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume

Cardiovascular Systems (CSII) Receives a Hold from Needham

TipRanks - Fri Jul 8, 8:15AM CDT
Needham analyst Michael Matson maintained a Hold rating on Cardiovascular Systems (CSIIResearch Report) today. The companys shares closed last Thursday at $14.96, close to its 52-week low of $13.41.

According to TipRanks.com, Matson is a 4-star analyst with an average return of 2.8% and a 47.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Merit Medical Systems.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cardiovascular Systems with a $22.67 average price target.

See today’s best-performing stocks on TipRanks >> The company has a one-year high of $43.37 and a one-year low of $13.41. Currently, Cardiovascular Systems has an average volume of 356.7K. Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CSII in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. Its products are catheter-based platforms capable of treating a range of vessel sizes and plaque types. The company was founded in 2000 and is headquartered in St. Paul, MN. Read More on CSII:

Paid Post: Content produced by TipRanks. The Globe and Mail was not involved, and material was not reviewed prior to publication.